CAR T-Cell Therapy Led to Remission in Rare Liver Cancer
A 3-year-old with treatment-resistant hepatoblastoma achieved a complete response lasting at least one year.
Updated on Sept. 28, 2026 in Cancer
In a report released in 2025, researchers detailed a case where an engineered CAR T-cell therapy induced a lasting complete response in a 3-year-old child with metastatic, chemotherapy-resistant hepatoblastoma. The patient, who had previously failed three lines of chemotherapy and surgery, remained in remission for at least one year following the treatment.
Why it matters
This case highlights potential progress for pediatric patients with aggressive liver cancers that do not respond to standard interventions. By offering a novel approach for treatment-resistant disease, the CARE trial seeks to improve survival outcomes in children who have exhausted conventional options.
A 3-year-old participant in the CARE trial achieved a complete response maintained for at least 1 year following two CAR T-cell infusions. While the results are promising for this individual, researchers note that long-term outcomes and safety for the wider trial population remain under study.
The players
CARE trial
An ongoing clinical study registered under NCT04715191 that evaluates the safety, feasibility, and preliminary efficacy of GPC3-targeted CAR T-cell therapy in pediatric patients.
The details
The experimental therapy uses autologous T cells engineered to target glypican-3, a protein frequently expressed on hepatoblastoma cells. To boost the immune system's effectiveness, the cells were modified to express cytokines IL-15 and IL-21, which support T-cell survival and activity. An inducible caspase-9 safety switch was also included to allow clinicians to deactivate the engineered cells if significant toxicity occurred.
Timeline
A complete response has been maintained for at least 1 year post-treatment.
Trial participants will undergo follow-up monitoring for 15 years.
Health Landscape
This report reflects the ongoing shift in pediatric oncology toward using engineered cell therapies to address solid tumors that resist conventional surgery and chemotherapy. It represents an early step in evaluating how targeted immune interventions can be adapted for rare pediatric liver malignancies.
This development is a preliminary research finding and does not currently change the standard of care for pediatric cancer patients. Families of children facing treatment-resistant hepatoblastoma may wish to discuss the availability of relevant clinical trials with their oncology team.
The takeaway
Targeted immunotherapy is being explored as an alternative for pediatric cancers that do not respond to traditional chemotherapy. For ongoing health management, parents should consult a pediatric oncologist about potential clinical trial participation when standard treatments prove ineffective.
Further reading
Learn more about the latest research and advancements in pediatric oncology by visiting our Cancer section.
More information
Review the full study design and participant criteria via the CARE trial clinical study record.
